NASDAQ:NSTG
NanoString Technologies Stock News
$0.105
+0 (+0%)
At Close: May 10, 2024
NanoString Highlights Groundbreaking Spatial Genomics Research at 2020 Advances in Genome Biology and Technology (AGBT) Conference
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
05:31pm, Wednesday, 19'th Feb 2020
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
05:31pm, Wednesday, 19'th Feb 2020
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString to Present at the 40th Annual Cowen Healthcare Conference
11:00am, Tuesday, 18'th Feb 2020
NanoString to present at the 40th annual Cowen Healthcare conference.
Nanostring Technologies Inc (NSTG) President and CEO R Bradley Gray Sold $67—,6…… of Shares
12:00am, Tuesday, 18'th Feb 2020Broadfin Capital, LLC Buys Staar Surgical Co, Alkermes PLC, Quotient, Sells Allergan PLC, Nevro ...
12:00am, Monday, 17'th Feb 2020NanoString Technologies Inc (NASDAQ:NSTG) Stock Holdings Lessened by Cutler Group LP
03:31pm, Friday, 14'th Feb 2020
Cutler Group LP cut its holdings in NanoString Technologies Inc (NASDAQ:NSTG) by 77.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,400 shares of the biot
Nanostring Technologies Inc (NSTG) President and CEO R Bradley Gray Sold $6'7,4…… of Shares
12:00am, Thursday, 13'th Feb 2020
According to Arizton's recent research report, Transplant Diagnostics Market - Global Outlook and Forecast 2020-2025 is expected to grow at a CAGR of approximately 7% during the period 2019−2025.
NanoString Announces Q4-2019 Quarterly Conference Call
Stocks Showing Rising Market Leadership: NanoString Technologies Earns 86 RS Rating
12:00am, Friday, 07'th Feb 2020
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced new data on the identific
